JK500 cell injection / Escure Biotech 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
JK500 cell injection / Escure Biotech
NCT05519384: Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia

Recruiting
1
12
RoW
JK500 cell injection，cyclophosphamide，Fludarabine
Institute of Hematology & Blood Diseases Hospital, Bejing Institute for Stem Cell and Regenerative Medicine, Institute for Stem cell and Regeneration, Chinese Academy of Sciences
Acute Myeloid Leukemia, Childhood, Relapsed Leukemia, Refractory Leukemia
11/23
12/25
ChiCTR2200062539: Safety and preliminary efficacy of JK500 cell injection in relapsed/refractory pediatric acute myeloid leukemia

Not yet recruiting
1
12
 
JK500 cell injection
Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences; Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences, Provided by the partner
relapsed/refractory pediatric acute myeloid leukemia
 
 

Download Options